Susquehanna International Group
BCTX

Susquehanna International Group’s Briacell Therapeutics BCTX Stock Holding History

Susquehanna International Group’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-337
Closed -$28.6K – 12476
2024
Q4 		$28.6K Buy
337
+244
+262% +$29.2K ﹤0.01% 11848
2024
Q3 		$17.2K Buy
93
+11
+13% +$1.24K ﹤0.01% 11656
2024
Q2 		$14.1K Hold
82
– – ﹤0.01% 11730
2024
Q1 		$35.3K Sell
82
-333
-80% -$184K ﹤0.01% 11664
2023
Q4 		$365K Buy
415
+68
+20% +$48.8K ﹤0.01% 9403
2023
Q3 		$325K Buy
347
+221
+175% +$216K ﹤0.01% 9190
2023
Q2 		$121K Sell
126
-78
-38% -$77K ﹤0.01% 10785
2023
Q1 		$228K Buy
+204
New +$212K ﹤0.01% 10306

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Susquehanna International Group's BCTX Position: Q1 2025 in Review

Susquehanna International Group sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 337 shares — an estimated $28.6K sold.

Susquehanna International Group first reported a position in BCTX in Q1 2023 and held it in 8 quarters. The position peaked at $365K in Q4 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Susquehanna International Group reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 337 Briacell Therapeutics shares in Q1 2025, an estimated $28.6K.
  • Susquehanna International Group first reported a position in Briacell Therapeutics in Q1 2023 and held it in 8 quarters.
  • Susquehanna International Group's Briacell Therapeutics position peaked at $365K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.